UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) JULY 31, 2003
------------------------------
GENENCOR INTERNATIONAL, INC.
-------------------------------------------------------------------------------
(Exact name of registrant as specified in charter)
DELAWARE 000-31167 16-1362385
-------------------------------------------------------------------------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
925 PAGE MILL ROAD, PALO ALTO, CALIFORNIA 94304
-------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (650) 846-7500
---------------------------
-------------------------------------------------------------------------------
(Former name or former address, if changed since last report)
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
(c) Exhibits
The following exhibit is furnished pursuant to Item 12:
Exhibit 99.1 - Press release issued by Genencor International, Inc. on
July 31, 2003 regarding its financial results for the
second quarter of 2003.
ITEM 12. RESULTS OF OPERATIONS AND FINANCIAL CONDITION.
The information contained in this report is being "furnished" and shall
not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act
of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities
of that section, nor shall it be incorporated by reference into any filing
pursuant to the Securities Act of 1933, as amended, or the Exchange Act.
On July 31, 2003, Genencor International, Inc. (the "Company") issued a
press release regarding its financial results for the quarter and six months
ended June 30, 2003. The press release is attached hereto as Exhibit 99.1 and is
incorporated herein by reference.
In addition to disclosing results that are determined in accordance with
Generally Accepted Accounting Principles ("GAAP"), in the press release the
Company also discloses non-GAAP financial measures that exclude the effects of
restructuring and related charges recorded in the six month period in 2002 on
consolidated net income available to common stockholders and diluted earnings
per share and on the operating income of its Bioproducts segment. The Company is
presenting non-GAAP financial measures excluding the effects of the
restructuring and related charges because the Company believes it is useful for
investors in assessing the Company's financial results compared to the same
period in the prior year. Within the text of the attached release and in
connection with each non-GAAP financial measure presented therein, the Company
has presented the most directly comparable financial measure calculated in
accordance with GAAP and has provided a reconciliation of the differences
between the non-GAAP financial measure with its most directly comparable
financial measure calculated and presented in accordance with GAAP.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this Report to be signed on its behalf by the
undersigned hereunto duly authorized.
GENENCOR INTERNATIONAL, INC.
Dated: July 31, 2003 By: /s/ Raymond J. Land
--------------------------
Raymond J. Land,
Senior Vice President and Chief
Financial Officer
EXHIBIT INDEX
Exhibit Number Description
-------------- ------------------------------------------------------------
99.1 Press release issued by Genencor International, Inc. on July 31, 2003
regarding its financial results for the second quarter of 2003.